Urinary System Carcinoma — Trials

Urinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 670
Recruiting: 353
Ph III recruiting: 41
Growth YoY: +12.6%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (391)

clinicaltrialsPublishedShowing 351–352 of 352 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00134186	Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer	completed	Phase 2	43	Pharmacyclics LLC.INDUSTRY	1	Mar 5, 2007	clinicaltrials
NCT00191711	Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.	completed	Phase 2	43	Eli Lilly and CompanyINDUSTRY	1	Jan 26, 2007	clinicaltrials